6 completed, 1 withdrawn. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow AmpliMed Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer Imexon + docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 2 | Withdrawn | AmpliMed Corporation | 2010-08-01 | 2015-06-24 | |
| A Randomized Study of Amplimexon (Imexon) With Gemcitabine in Pancreatic Cancer imexon in combination with gemcitabine, imexon placebo + gemcitabine - Pancreatic Neoplasms | Phase 2 | Completed | AmpliMed Corporation | 142 | 2008-04-01 | 2019-03-20 |
| Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy imexon - Neoplasm Metastasis | Phase 1 | Completed | AmpliMed Corporation | 18 | 2005-11-01 | 2008-03-14 |
| Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients imexon - Multiple Myeloma | Phase 1 / Phase 2 | Completed | AmpliMed Corporation | 2005-10-01 | 2009-08-11 | |
| Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients imexon, docetaxel - Non-small Cell Lung Cancer, Breast Cancer | Phase 1 | Completed | AmpliMed Corporation | 34 | 2005-10-01 | 2015-06-24 |
| Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma imexon, DTIC - Malignant Melanoma | Phase 1 / Phase 2 | Completed | AmpliMed Corporation | 68 | 2005-07-01 | 2010-09-15 |
| Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma imexon, gemcitabine - Pancreatic Adenocarcinoma | Phase 1 | Completed | AmpliMed Corporation | 105 | 2004-02-01 | 2010-09-15 |
Neoplasm Metastasis (3) · Carcinoma, Non-Small-Cell Lung (2) · Breast Neoplasms (1) · Melanoma (1) · Multiple Myeloma (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one (7) · Docetaxel (2) · Gemcitabine (2) · Dacarbazine (1)
United States (7)
Evan Hersh, MD (4) · Steven Cohen, MD (2) · Mark Zalupski, MD (1)